Taiwan Liposome Company Ltd ADR (TLC) Stock Price & Overview
NASDAQ:TLC
Current stock price
The current stock price of TLC is 7 null. Today TLC is down by 0%. In the past month the price decreased by -2.78%. In the past year, price increased by 59.45%.
TLC Key Statistics
- Market Cap
- 294.539M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.69
- Dividend Yield
- N/A
TLC Stock Performance
TLC Stock Chart
TLC Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TLC. When comparing the yearly performance of all stocks, TLC is one of the better performing stocks in the market, outperforming 84.9% of all stocks.
TLC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TLC. TLC has a bad profitability rating. Also its financial health evaluation is rather negative.
TLC Earnings
TLC Forecast & Estimates
For the next year, analysts expect an EPS growth of 4.76% and a revenue growth -35.08% for TLC
TLC Financial Highlights
Over the last trailing twelve months TLC reported a non-GAAP Earnings per Share(EPS) of -0.69. The EPS increased by 21.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -291.85% | ||
| ROA | -60.71% | ||
| ROE | N/A | ||
| Debt/Equity | 0.67 |
TLC Ownership
About TLC
Company Profile
Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company's product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan.
Company Info
Taiwan Liposome Company Ltd ADR
11TH FLOOR-1 YUANQU STREET NANGANG DISTRICT
TAIPEI CITY F5 11503
CEO: Keelung Hong
Phone: 886-2-2655-7377
Taiwan Liposome Company Ltd ADR / TLC FAQ
Can you describe the business of Taiwan Liposome Company Ltd ADR?
Taiwan Liposome Company Ltd. is a specialty pharmaceutical company. It focuses on development and commercialization of novel nanomedicines designed to target unmet medical need in pain management, ophthalmology and oncology. The company's product pipeline consists of TLC599, TLC590, TLC399 and TLC178 which are in clinical stage. Taiwan Liposome Company Ltd. is headquartered in Taipei City, Taiwan.
What is the current price of TLC stock?
The current stock price of TLC is 7 null.
Does TLC stock pay dividends?
TLC does not pay a dividend.
What is the ChartMill technical and fundamental rating of TLC stock?
TLC has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of Taiwan Liposome Company Ltd ADR (TLC)?
Taiwan Liposome Company Ltd ADR (TLC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.69).
What is the expected growth for TLC stock?
The Revenue of Taiwan Liposome Company Ltd ADR (TLC) is expected to decline by -35.08% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.